ArticleEuropean journal of nuclear medicine and molecular imaging2026
Enhancing interpretability of AI with radiomics-based deep neural network: proof of concept in the classification of Parkinsonian syndromes with
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A review of FDG-PET biomarker analysis methods in Parkinson's disease.Journal of Parkinson's disease · 2026Review
- RDoC-informed explainable AI as a paradigm for multilevel Alzheimer's disease diagnosis and progression prediction: a systematic review.Brain informatics · 2026Review
- Differentiating early Parkinson's disease from multiple system atrophy on multimodal PET/MRI using atlas-guided segmentation and vision transformer classification.Frontiers in aging neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveInterpretability and reproducibility remain major challenges in applying deep neural network (DNN) to neuroimaging-based diagnosis. This study proposes a radiomics-guided dual-channel deep neural network (RDDNN) to improve feature transparency and enhance clinical understanding in the classification of Parkinsonian syndromes.
methodsIn this bi-centric study, we analysed two independent cohorts comprising 1,275 patients with idiopathic Parkinson's disease (IPD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP), alongside 223 healthy controls from Huashan Hospital and 90 patients with IPD, MSA, and PSP (34IPD, 17MSA, 39PSP) from the University Hospital Munich. It is a re-analysis of well-studied Chinese and German cohorts of
resultsIn the internal blind-test cohort, the RDDNN achieved high accuracy (AUC = 0.99, accuracy = 0.98). SHAP and correlation analyses jointly indicated complementary information across channels, some of which were clinically interpretable. In the external cohort, the model maintained robust performance (AUC = 0.94, accuracy = 0.81), with consistent feature patterns across populations. The model significantly reduced evaluation time compared to nuclear medicine specialists' readings (p < 0.001), and the heatmaps showed disease-specific activation in anatomically relevant regions for IPD, MSA, and PSP.
conclusionThe RDDNN framework provides a clinically interpretable and reproducible DNN solution for classifying Parkinsonian disorders. By integrating radiomics and attention-based modeling, it enhances lesion localization, supports clinical decision-making, and offers performance comparable to human specialists-while substantially improving diagnostic efficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.